Abstract

Objective: To evaluate the visual outcomes and complications of phakic intraocular lenses Implantation for myopia. Method: This cross sectional study included 151 myopic eyes implanted with one of the three types of phakic intraocular lenses (Artisan 83 eyes, ICL 52 eyes, and I- Care 16 eyes). Patients were followed for an average of 33±15 months. Intraoperative and postoperative complications were recorded as short- term and long-term. All patients were recalled and examined under thorough eye examination. Results: Three years after the surgery, safety index has changed significantly using the Artisan and ICL lenses respectively (P>0.001 and P 0.007=) and efficacy index in the three groups was 0.04 ± 0.91, 0.14± 1.61 and ± 0.42 0.15. Spherical Equivalent (SE) values decreased post operation that was statistically significant (P 001/0>) using Artisan and ICL lenses. Also, Astigmatism values dropped significantly using Artisan and I-care lenses (P 001/0> and P 03/0=) three years after surgery. Endothelial cell count reduction percentage was 6.1% and 5.2% in groups Arti san and ICL respectively, while it was 43.7% in Group ICare. Conclusion: No significant intraoperative complication was seen among the three groups. However, sharp decline of post operatively corneal endothelial cell count was the most important complication of I- Care lens and it is suggested to prevent implantation of this type of PIOLs for anticipation of cornea decompensation.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.